These are top 10 stocks traded on the Robinhood UK platform in July
On Wednesday, H.C. Wainwright analyst Raghuram Selvaraju affirmed a Buy rating on Microbot Medical (NASDAQ:MBOT) shares with a consistent price target of $9.00. The stock, currently trading at $1.65, has shown strong momentum with a 69% surge over the past six months. According to InvestingPro data, the company maintains a healthy balance sheet with more cash than debt. The endorsement follows the recent presentation of favorable results from the ACCESS-PVI pivotal trial of the LIBERTY endovascular robotic system. The trial's findings were shared at the Society of Interventional Radiology (SIR) annual meeting.
The LIBERTY system's trial was conducted across three leading medical institutions: Memorial Sloan Kettering Cancer Center in New York, Baptist Hospital of Miami, and Brigham and Women's Hospital in Boston. The trial successfully met its primary endpoint with a 100% success rate in robotic navigation across all cases (n=20). Additionally, no Adverse Device Events (ADE) were reported throughout the follow-up period. With an overall Financial Health score of FAIR from InvestingPro, the company appears positioned to advance its innovative technology.
A significant outcome of the trial was the substantial reduction in radiation exposure for operators. The data indicated a mean relative decrease of 92% in radiation exposure when compared to control. Median time for robotic navigation to the target area was recorded at three minutes. Physicians involved in the trial also reported complete satisfaction with the performance of the LIBERTY system.
In light of these positive results, H.C. Wainwright has raised the probability of FDA 510(k) clearance for the LIBERTY system to 80%, up from the previous 70%. The firm's estimated market value has consequently increased to $308 million, significantly above the current market capitalization of $57.33 million. With an anticipated 34.8 million shares outstanding by the end of 2025, the analyst's price objective stands at approximately $9 per share, leading to the reiterated Buy rating and price target. Discover more valuable insights and 8 additional ProTips for MBOT with InvestingPro.
In other recent news, Microbot Medical Inc. has reported significant developments, including the results of its ACCESS-PVI pivotal trial and various financial activities. The trial demonstrated a 100% success rate in robotic navigation using the LIBERTY® Endovascular Robotic System, with a notable reduction in radiation exposure for operators. The company has submitted a 510(k) premarket notification to the FDA for this system and anticipates clearance in the second quarter of 2025. In terms of fundraising, Microbot Medical raised approximately $20.6 million through several securities offerings and concluded an At-the-Market offering agreement with H.C. Wainwright & Co.
Additionally, Microbot Medical has regained compliance with Nasdaq's minimum bid price requirement, which is crucial for maintaining its listing status. The company also announced executive compensation adjustments, with salary increases for key executives and a special bonus of $150,000 awarded to CEO Harel Gadot. Despite the ongoing Israel-Hamas conflict, Microbot Medical has not experienced material adverse effects on its operations. The company continues to focus on its commercial and regulatory goals while navigating the competitive landscape in medical robotics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.